Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 26 | ECE2011 | Next issue

13th European Congress of Endocrinology

Symposia

Emerging therapies in type 2 diabetes

ea0026s15.1 | Emerging therapies in type 2 diabetes | ECE2011

Emerging therapies in type 2 diabetes: bariatric surgery

Cardoso Helena

The biggest achievement of bariatric surgery was to demonstrate that obesity co-morbidity improve or even reverse with long-term weight control. This evidence was achieved with the Swedish Obesity Study for mortality and diabetes incidence.Diabetes resolution rates range from 55 to 96% depending on the surgical procedure and length of follow-up. Diabetes improvement or resolution almost reaching the 100%. The type of surgery seems to play a role in diabe...

ea0026s15.2 | Emerging therapies in type 2 diabetes | ECE2011

11β-Hydroxysteroid dehydrogenase inhibitors for treatment of metabolic syndrome

Stewart P , Cooper M , Lavery G , Tomlinson J

Harvey Cushing’s work informed us of the deleterious consequences of circulating cortisol excess – hypertension, osteoporosis and obesity that contributes to diabetes and premature mortality. Conversely, Hench, Kendall and Reichstein were Nobel Laureates in Physiology 1950 for the discovery of cortisone and demonstrating efficacy in patients with Rheumatoid Arthritis – in effect the birth of the anti-inflammatory actions of glucocorticoids.<p class="abstext"...

ea0026s15.3 | Emerging therapies in type 2 diabetes | ECE2011

Future therapies – what is in the pipeline?

Sorensen Torekov Signe

Incretin-based therapies, such as the injectable GLP-1 receptor agonists and orally administered DPP-4 inhibitors, have recently been introduced into clinical practice. At present, the GLP-1 receptor agonists need to be administered once or twice daily. Several once weekly GLP-1 receptor agonists are in phase 3 development. This review examines the efficacy, safety and perspective for the future of the once weekly GLP-1 receptor agonists: exenatide once weekly, taspoglutide, a...